Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

Inclusion Criteria: * Patient is more than 40 and less than 70 years of age. * Patient has confirmed osteoarthritis (OA) and/or rheumatoid arthritis (RA) and could benefit from NSAID therapy. * No current gastrointestinal H. pylori infection. Exclusion Criteria: * Known allergy or hypersensitivity to NSAIDs, or has any other contraindicated condition(s) to NSAID therapy. * Patient has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the Screening Visit, or has had a bowel resection at any time. * Medical history includes prior or active GI complications and/or disorders, including but not limited to Barrett's esophagus, erosive esophagitis, esophageal stricture or ring, gastric obstruction, irritable bowel syndrome (IBS), or inflammatory bowel disease (IBD). * Active symptomatic peptic ulcer disease or GI bleeding. * Patient has received cobiprostone (SPI-8811; RU-8811) or AMITIZA (other names: lubiprostone, SPI-0211, or RU-0211) at any time prior to participation in this study.